Who are Levomethamphetamine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Paremyd, Levamphetamine, Methamphetamine Hydrochloride Tablets, Norden, SEP363856, SEP-363856.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levmetamfetamine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Levomethamphetamine — Competitive Intelligence Brief

Levomethamphetamine (LEVMETAMFETAMINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: levmetamfetamine. Area: Hematology.

marketed levmetamfetamine Trace amine-associated receptor 1 Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Levomethamphetamine (LEVMETAMFETAMINE).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Levomethamphetamine TARGET	LEVMETAMFETAMINE		marketed	levmetamfetamine	Trace amine-associated receptor 1
Paremyd	hydroxyamfetamine	Pharmics	marketed	Adrenergic Receptor Agonist	Trace amine-associated receptor 1	1969-01-01
Levamphetamine	LEVAMFETAMINE		marketed	levamfetamine	Sigma non-opioid intracellular receptor 1, Trace amine-associated receptor 1, Serotonin (5-HT) receptor
Methamphetamine Hydrochloride Tablets	Methamphetamine Hydrochloride Tablets	Oregon Health and Science University	marketed	Sympathomimetic amine; central nervous system stimulant	Dopamine transporter (DAT); norepinephrine transporter (NET); trace amine-associated receptor 1 (TAAR1)
Norden	OCTOPAMINE		marketed	octopamine	5-hydroxytryptamine receptor 3A, Trace amine-associated receptor 1, Trace amine-associated receptor 1
SEP363856	SEP363856	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	TAAR1 agonist	TAAR1 (trace amine-associated receptor 1)
SEP-363856	SEP-363856	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	TAAR1 agonist	TAAR1 (trace amine-associated receptor 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (levmetamfetamine class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levomethamphetamine — Competitive Intelligence Brief. https://druglandscape.com/ci/levmetamfetamine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab